Back to top
more

Stryker (SYK)

(Delayed Data from NYSE)

$377.58 USD

377.58
972,333

+1.21 (0.32%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $377.57 -0.01 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (153 out of 244)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

National Vision's (EYE) Q1 Earnings Beat, Margins Decline

by Zacks Equity Research

National Vision's (EYE) consistent strength in comps is owing to higher customer transaction for the past 69 straight quarters.

Zacks Equity Research

Syneos' (SYNH) Q1 Earnings Miss Estimates, Revenues In Line

by Zacks Equity Research

Syneos Health (SYNH) sees strong year-over-year revenue growth across both operating segments ??? Clinical Solutions and Commercial Solutions.

Zacks Equity Research

LHC Group (LHCG) Earnings Beat, Revenues Miss Estimates in Q1

by Zacks Equity Research

LHC Group (LHCG) gains from solid home health services in Q1, raises 2019 view.

Zacks Equity Research

BioScrip's Option Care Merger on Track, Q1 Loss Narrows

by Zacks Equity Research

BioScrip (BIOS) is highly upbeat about the strategic and financial virtues of Option Care consolidation.

Zacks Equity Research

Cardinal Health (CAH) Q3 Earnings Top Estimates, Revenues Lag

by Zacks Equity Research

Cardinal Health (CAH) Q3 results benefit from strong performance by Pharmaceutical segment and higher revenues. However, sluggishness in the Medical segment remains a concern.

Zacks Equity Research

Bio-Rad (BIO) Q1 Earnings Beat Estimates, Margins Expand

by Zacks Equity Research

Bio-Rad (BIO) witnesses revenue growth at the Life Sciences segment in Q1 on strength in cell biology, droplet Digital PCR and other product lines.

Zacks Equity Research

Wright Medical (WMGI) Q1 Earnings & Revenues Top Estimates

by Zacks Equity Research

Wright Medical (WMGI) Q1 results benefit from higher revenues, solid show by Lower as well as Upper Extremities segments and gross margin expansion. However, rising costs remain a woe.

Zacks Equity Research

OPKO Health (OPK) Reports Loss in Q1, Misses Revenue Estimates

by Zacks Equity Research

Lower revenues, weak performing product segment and contraction in gross margin impact OPKO Health's (OPK) Q1 results.

Zacks Equity Research

Becton, Dickinson (BDX) Q2 Earnings Beat, Revenues Fall Y/Y

by Zacks Equity Research

Becton, Dickinson (BDX) gains from BD Medical in fiscal Q2; international revenues down.

Zacks Equity Research

Phibro's (PAHC) Q3 Earnings Miss Estimates, Margins Fall

by Zacks Equity Research

Phibro Animal Health (PAHC) sees year-over-year revenue decline in two core segments ??? Animal Health and Mineral Nutrition.

Zacks Equity Research

Haemonetics (HAE) Q4 Earnings Top Mark, Operating Margin Up

by Zacks Equity Research

A steady momentum in new business wins and consistent geographical expansion drive Haemonetics' (HAE) top-line results

Zacks Equity Research

Bruker (BRKR) Q1 Earnings Beat Estimates, Guidance Upbeat

by Zacks Equity Research

Bruker's (BRKR) current focus on product development through higher R&D investment stokes investors' positive sentiment around the stock.

Zacks Equity Research

McKesson (MCK) Q4 Earnings Beat, Revenues Miss Estimates

by Zacks Equity Research

McKesson's (MCK) Q4 results benefit from higher revenues, gross margin expansion and solid show by U.S. Pharmaceutical and Specialty Solutions.

Zacks Equity Research

Avanos (AVNS) Q1 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Avanos (AVNS) Q1 results benefit from higher revenues, strong segmental performance and expansion in margins.

Zacks Equity Research

Allscripts (MDRX) Q1 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Allscripts (MDRX) Q1 results gain from growth in bookings and solid show by client services segment. Contraction in margins remains a woe.

Zacks Equity Research

Genomic Health (GHDX) Q1 Earnings Top Estimates, Margins Up

by Zacks Equity Research

Genomic Health (GHDX) registers strong year-over-year growth in revenues on solid domestic and overseas performances.

Zacks Equity Research

Inogen (INGN) Earnings Miss Estimates in Q1, View Lowered

by Zacks Equity Research

Inogen (INGN) slashes revenue and net income guidance for 2019.

Zacks Equity Research

DaVita (DVA) Earnings and Revenues Miss Estimates in Q1

by Zacks Equity Research

DaVita (DVA) gains from international revenues in Q1.

Zacks Equity Research

Myriad Genetics (MYGN) Q3 Earnings Top Estimates, Revenues Up

by Zacks Equity Research

Myriad Genetics (MYGN) observes strong year-over-year revenue growth in EndoPredict, Hereditary Cancer and Prolaris testing as well as pharmaceutical and clinical service segments.

Urmimala Biswas headshot

Henry Schein's (HSIC) Q1 Earnings, Revenues Beat Estimates

by Urmimala Biswas

Henry Schein's (HSIC) strong share gains in the North American market raise optimism.

Zacks Equity Research

Intersect (XENT) Q1 Loss Wider Than Estimates, Revenues Top

by Zacks Equity Research

Intersect (XENT) records revenue growth on increased adoption of the PROPEL family of products and SINUVA Sinus Implant.

Zacks Equity Research

QIAGEN's (QGEN) Q1 Earnings Top Estimates, Revenues Miss

by Zacks Equity Research

QIAGEN (QGEN) sees year-over-year growth across all segments and majority of geographies.

Zacks Equity Research

Masimo (MASI) Q1 Earnings and Revenues Beat, Guidance Solid

by Zacks Equity Research

Solid non-invasive revenues boost Masimo's (MASI) Q1; guidance raised.

Zacks Equity Research

Pacific Biosciences (PACB) Incurs Loss in Q1, Revenues Fall

by Zacks Equity Research

Pacific Biosciences' (PACB) segments see softness in Q1; merger with Illumina on track.

Zacks Equity Research

Luminex (LMNX) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Luminex (LMNX) Q1 results gain from higher revenues from System sales, Royalty as well as Service segments. However, contraction in gross margin remains a woe.